Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
出版年份 2021 全文链接
标题
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 22, Issue 5, Pages 690-701
出版商
Elsevier BV
发表日期
2021-03-31
DOI
10.1016/s1470-2045(21)00027-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN
- (2020) A. Demols et al. ANNALS OF ONCOLOGY
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Reaching out beyond first-line treatments in advanced biliary tract cancers
- (2020) A. Lamarca et al. ANNALS OF ONCOLOGY
- 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial
- (2020) J.M. Phelip et al. ANNALS OF ONCOLOGY
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
- (2019) Maeve A. Lowery et al. CANCER
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
- (2018) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
- (2017) Peter M Bruno et al. NATURE MEDICINE
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder
- (2016) S D Kaupp-Roberts et al. BRITISH JOURNAL OF CANCER
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
- (2015) J. Bridgewater et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Early integration of palliative care services with standard oncology care for patients with advanced cancer
- (2013) Joseph A. Greer et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study
- (2012) Thomas Walter et al. EUROPEAN JOURNAL OF CANCER
- Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
- (2011) E Friend et al. BRITISH JOURNAL OF CANCER
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness
- (2010) Sung Yong Oh et al. INVESTIGATIONAL NEW DRUGS
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
- (2009) Suee Lee et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started